FDA's Cell and Gene Therapy Regulatory Team Collective Suspension, Gene Editing Stocks Hit Again

Finance app Wise Finance News noted that on Friday, the stock prices of gene editing companies remained stable overall in the early trading session of the US stock market, but later followed the market down. Prior to this, there was another sudden personnel change at the Center for Biologics Evaluation and Research (CBER) of the US FDA - following the sudden departure of Dr. Peter Marks, the former director, at the beginning of the year, the deputy directors of the Cell and Gene Therapy department were collectively suspended on Wednesday.